Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.

The EU recommendation for odronextamab comes after a US rejection in March.

But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.

Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.

Earnings season begins again, while big readouts loom for ALX and Fibrogen.

A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.

The ROR1 data are sketchy, and lung toxicity clouds prospects.